Jankowiak Berenika, Wleklik Marta, Rosiek-Biegus Marta
Institute of Heart Diseases, Wroclaw Medical University, 50-556 Wroclaw, Poland.
Division of Research Methodology, Department of Nursing, Faculty of Nursing and Midwifery, Wroclaw Medical University, 50-556 Wroclaw, Poland.
Vaccines (Basel). 2024 Nov 26;12(12):1321. doi: 10.3390/vaccines12121321.
Heart failure (HF) affects 64 million people worldwide and is one of the most prevalent causes of hospitalization in adults. Infection is believed to be one of the potential triggers that may facilitate HF decompensation and the need for hospitalization. Therefore, it seems crucial to safeguard against such a situation. Vaccinations seem to be a very reasonable option. However, this remains an underutilized solution among HF patients. This review investigates the impact of available vaccinations, including influenza, COVID-19, pneumococcal, and RSV, on prognosis in specific HF populations only, as there are pathophysiological reasons to believe that this population of patients may benefit the most from the intervention. It will provide information about the safety profile of these vaccines and summarize the available evidence on their impact on hard clinical outcomes. In summary, this article will discuss the impact of preventive vaccinations against seasonal infections in the HF population.
心力衰竭（HF）影响着全球6400万人，是成年人住院治疗最常见的原因之一。感染被认为是可能促使HF失代偿和需要住院治疗的潜在触发因素之一。因此，防范这种情况似乎至关重要。接种疫苗似乎是一个非常合理的选择。然而，在HF患者中，这仍然是一种未得到充分利用的解决方案。本综述仅研究现有疫苗（包括流感疫苗、新冠疫苗、肺炎球菌疫苗和呼吸道合胞病毒疫苗）对特定HF人群预后的影响，因为有病理生理学原因认为这一患者群体可能从干预措施中获益最大。它将提供有关这些疫苗安全性的信息，并总结关于它们对硬性临床结局影响的现有证据。总之，本文将讨论预防性接种疫苗对HF人群季节性感染的影响。
